Biota Pharmaceuticals

The Company has four product candidates in development that address viral infections that have limited therapeutic options.
We are currently enrolling patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second Phase 2 clinical product candidate is BTA074 (AP611074), a novel topical treatment for genital warts caused by HPV types 6 & 11. We also are developing BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections. We anticipate beginning a Phase 1 clinical trial with BTA-C585 in Q3 2105. Laninamivir octanoate, a one-time, inhaled neuraminidase for the treatment of influenza A and B infections has completed a global Phase 2 trial. 
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.

Type
Public
HQ
Alpharetta, US
Founded
1984
Size (employees)
19 (est)
Biota Pharmaceuticals was founded in 1984 and is headquartered in Alpharetta, US

Biota Pharmaceuticals Office Locations

Biota Pharmaceuticals has an office in Alpharetta
Alpharetta, US (HQ)
100 2500 Northwinds Pkwy

Biota Pharmaceuticals Data and Metrics

Biota Pharmaceuticals Financial Metrics

Biota Pharmaceuticals's revenue was reported to be $4.9 m in Q3, 2017
USD

Revenue (Q3, 2017)

4.9 m

Net income (Q3, 2017)

(4.4 m)

EBIT (Q3, 2017)

(3.8 m)

Cash (31-Mar-2017)

11.8 m
USDFY, 2014FY, 2015FY, 2016

Revenue

68.7 m24.6 m9.3 m

Revenue growth, %

(64%)(62%)

Cost of goods sold

51.1 m3.6 m

Gross profit

17.6 m21 m

Gross profit Margin, %

26%85%

R&D expense

26.3 m

General and administrative expense

8 m

Operating expense total

80.2 m44.1 m34.5 m

EBIT

(11.5 m)(19.5 m)(25.2 m)

EBIT margin, %

(17%)(79%)(271%)

Net Income

(11 m)(19.1 m)(25.4 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

700 k13.9 m5.9 m1.7 m1.7 m5.3 m100 k3.8 m4.9 m

Cost of goods sold

1.7 m1.6 m300 k

Gross profit

(1 m)12.3 m5.6 m

Gross profit Margin, %

(143%)88%95%

R&D expense

4.9 m4.8 m4.8 m5.5 m6.3 m8.5 m7.6 m10.2 m6.8 m

General and administrative expense

2.4 m2.6 m3.2 m2.2 m2.1 m2.3 m2.2 m2.1 m1.8 m

Operating expense total

7.3 m7.4 m8 m7.7 m8.4 m10.8 m9.8 m12.3 m8.6 m

EBIT

(7 m)6.4 m1.1 m(6.7 m)(6.5 m)(5.2 m)(9.6 m)(8.6 m)(3.8 m)

EBIT margin, %

(1000%)46%19%(394%)(382%)(98%)(9600%)(226%)(78%)

Interest income

100 k100 k100 k100 k100 k100 k

Pre tax profit

(6.6 m)

Income tax expense

100 k200 k

Net Income

(6.9 m)6.5 m1.2 m(6.6 m)(6.5 m)(5.2 m)(10 m)(9.1 m)(4.4 m)
USDFY, 2014FY, 2015FY, 2016

Cash

81.7 m44.7 m49.7 m

Current Assets

101.1 m70.8 m72.4 m

PP&E

2 m200 k300 k

Total Assets

114 m79.4 m72.7 m

Accounts Payable

2.8 m1.9 m3.9 m

Current Liabilities

26.9 m9 m9.2 m

Total Liabilities

26.5 m

Additional Paid-in Capital

146.4 m155.6 m157.6 m

Retained Earnings

(89.8 m)(108.9 m)(134.3 m)

Total Equity

86.9 m69.5 m46.2 m

Financial Leverage

1.3 x1.1 x1.6 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Cash

57.7 m63.7 m61.5 m45.3 m39 m30.6 m45.9 m38.1 m11.8 m

Accounts Receivable

10.1 m3.2 m

Current Assets

76.1 m86.2 m87.4 m61.2 m58.6 m60.5 m62.8 m56.2 m46.4 m

PP&E

1.6 m1.1 m300 k200 k400 k400 k300 k300 k300 k

Total Assets

97.3 m93.4 m88.8 m71 m64.2 m61.9 m63.1 m56.5 m46.7 m

Accounts Payable

1.4 m1.7 m1 m2.9 m1.3 m3.7 m1.6 m3.4 m1.8 m

Current Liabilities

19.3 m10.9 m7.2 m6.7 m6 m8.7 m8.8 m10.5 m5.5 m

Additional Paid-in Capital

146.8 m147.4 m148 m156.2 m156.8 m157.2 m158 m158.5 m159.1 m

Retained Earnings

(96.7 m)(90.2 m)(89 m)(115.5 m)(122.1 m)(127.3 m)(144.3 m)(153.4 m)(157.8 m)

Total Equity

63.5 m57.5 m52.7 m36.6 m28 m24.2 m

Financial Leverage

1.1 x1.1 x1.2 x1.7 x2 x1.9 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(11 m)(19.1 m)(25.4 m)

Depreciation and Amortization

2.4 m1.1 m100 k

Accounts Receivable

(7.1 m)6.2 m11.9 m

Cash From Operating Activities

(3.3 m)(9.6 m)(14.1 m)

Purchases of PP&E

(100 k)(100 k)(200 k)

Cash From Investing Activities

(10.1 m)(19.4 m)1.3 m

Cash From Financing Activities

26.8 m(100 k)17.8 m
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(6.9 m)6.5 m1.2 m(6.6 m)(6.5 m)(5.2 m)(10 m)(9.1 m)(4.4 m)

Accounts Receivable

10.1 m3.2 m

Accounts Payable

1.4 m1.7 m1 m2.9 m1.3 m3.7 m1.6 m3.4 m1.8 m
Y, 2017

Financial Leverage

1.9 x

Biota Pharmaceuticals Operating Metrics

FY, 2016

Phase II Trials

4

Marketed Vaccines

2

Biota Pharmaceuticals Company Life and Culture

You may also be interested in